FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2097029797> ?p ?o ?g. }

• W2097029797 endingPage "162" @default.
• W2097029797 startingPage "157" @default.
• W2097029797 abstract "Intraperitoneal chemotherapy has a strong biological and pharmacological rationale in the treatment of ovarian cancer. From 1989 to 1996 the present study included 113 patients with FIGO stage II-IV ovarian cancer with residual disease less than 2 cm who were randomly allocated to receive 50 mg/m(2) intraperitoneal cisplatin (CDDP) plus 60 mg/m(2) intravenous epidoxorubicin (EPIDOX) and 600 mg/m(2) intravenous cyclophosphamide (CTX) (ipPEC arm) or 50 mg/m(2) intravenous CDDP plus 60 mg/m(2) intravenous EPIDOX and 600 mg/m(2) intravenous CTX (ivPEC arm). Chemotherapy was repeated every 4 weeks for six cycles. Treatment protocol was changed in 22 patients, 2 from the iv arm (who received single-agent carboplatin) and 20 from the ip arm (who were crossed to systemic chemotherapy, ivPEC, or single-agent carboplatin). At the end of chemotherapy, a second-look was performed in 33 of the 54 patients from the ip arm and in 34 of the 57 patients from the systemic arm. The pathologic complete response rate was 41% of all entered patients and 69% of patients submitted to second-look. No significant difference in pathologic response rate as well as in hematologic and nonhematologic toxicities was seen between the two arms. Up to September 1998, 72 patients showed a disease recurrence (33 treated with ipPEC and 39 treated with ivPEC), 55 died (22 ipPEC and 30 ivPEC), and 10 were lost to follow-up (6 ipPEC and 4 ivPEC). Median progression-free survival was 42 and 25 months for ipPEC and ivPEC, respectively (p = 0.13). Median overall survival was 67 and 51 months for ipPEC and ivPEC, respectively (p = 0.14). In conclusion, besides confirming that intraperitoneal chemotherapy is feasible with acceptable toxicity but with poor compliance in community hospitals, this trial showed that intraperitoneal CDDP compared with intravenous CDDP in combination with EPIDOX and CTX obtained a slight (not significant) improvement in progression-free survival and overall survival of optimally cytoreduced advanced ovarian cancer patients." @default.
• W2097029797 created "2016-06-24" @default.
• W2097029797 creator A5015339379 @default.
• W2097029797 creator A5031708909 @default.
• W2097029797 creator A5034987953 @default.
• W2097029797 creator A5050114898 @default.
• W2097029797 creator A5068968117 @default.
• W2097029797 creator A5070738538 @default.
• W2097029797 creator A5074527671 @default.
• W2097029797 creator A5081516681 @default.
• W2097029797 date "2000-02-01" @default.
• W2097029797 modified "2023-09-23" @default.
• W2097029797 title "Intraperitoneal versus Intravenous Cisplatin in Combination with Intravenous Cyclophosphamide and Epidoxorubicin in Optimally Cytoreduced Advanced Epithelial Ovarian Cancer: A Randomized Trial of the Gruppo Oncologico Nord-Ovest" @default.
• W2097029797 cites W1758230404 @default.
• W2097029797 cites W1857437878 @default.
• W2097029797 cites W1871865048 @default.
• W2097029797 cites W1916178458 @default.
• W2097029797 cites W1944392621 @default.
• W2097029797 cites W2025656095 @default.
• W2097029797 cites W2079913422 @default.
• W2097029797 cites W2103862203 @default.
• W2097029797 cites W2129678716 @default.
• W2097029797 cites W2142114138 @default.
• W2097029797 cites W2173197466 @default.
• W2097029797 cites W2226590642 @default.
• W2097029797 cites W2233693505 @default.
• W2097029797 cites W2240049137 @default.
• W2097029797 cites W2261061437 @default.
• W2097029797 cites W2316501478 @default.
• W2097029797 cites W2328421677 @default.
• W2097029797 doi "https://doi.org/10.1006/gyno.1999.5677" @default.
• W2097029797 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10637064" @default.
• W2097029797 hasPublicationYear "2000" @default.
• W2097029797 type Work @default.
• W2097029797 sameAs 2097029797 @default.
• W2097029797 citedByCount "124" @default.
• W2097029797 countsByYear W20970297972012 @default.
• W2097029797 countsByYear W20970297972013 @default.
• W2097029797 countsByYear W20970297972014 @default.
• W2097029797 countsByYear W20970297972015 @default.
• W2097029797 countsByYear W20970297972016 @default.
• W2097029797 countsByYear W20970297972017 @default.
• W2097029797 countsByYear W20970297972018 @default.
• W2097029797 countsByYear W20970297972019 @default.
• W2097029797 countsByYear W20970297972021 @default.
• W2097029797 countsByYear W20970297972022 @default.
• W2097029797 countsByYear W20970297972023 @default.
• W2097029797 crossrefType "journal-article" @default.
• W2097029797 hasAuthorship W2097029797A5015339379 @default.
• W2097029797 hasAuthorship W2097029797A5031708909 @default.
• W2097029797 hasAuthorship W2097029797A5034987953 @default.
• W2097029797 hasAuthorship W2097029797A5050114898 @default.
• W2097029797 hasAuthorship W2097029797A5068968117 @default.
• W2097029797 hasAuthorship W2097029797A5070738538 @default.
• W2097029797 hasAuthorship W2097029797A5074527671 @default.
• W2097029797 hasAuthorship W2097029797A5081516681 @default.
• W2097029797 hasConcept C121608353 @default.
• W2097029797 hasConcept C126322002 @default.
• W2097029797 hasConcept C126894567 @default.
• W2097029797 hasConcept C141071460 @default.
• W2097029797 hasConcept C143998085 @default.
• W2097029797 hasConcept C2776694085 @default.
• W2097029797 hasConcept C2776755627 @default.
• W2097029797 hasConcept C2778239845 @default.
• W2097029797 hasConcept C2780427987 @default.
• W2097029797 hasConcept C2781451048 @default.
• W2097029797 hasConcept C71924100 @default.
• W2097029797 hasConcept C90924648 @default.
• W2097029797 hasConceptScore W2097029797C121608353 @default.
• W2097029797 hasConceptScore W2097029797C126322002 @default.
• W2097029797 hasConceptScore W2097029797C126894567 @default.
• W2097029797 hasConceptScore W2097029797C141071460 @default.
• W2097029797 hasConceptScore W2097029797C143998085 @default.
• W2097029797 hasConceptScore W2097029797C2776694085 @default.
• W2097029797 hasConceptScore W2097029797C2776755627 @default.
• W2097029797 hasConceptScore W2097029797C2778239845 @default.
• W2097029797 hasConceptScore W2097029797C2780427987 @default.
• W2097029797 hasConceptScore W2097029797C2781451048 @default.
• W2097029797 hasConceptScore W2097029797C71924100 @default.
• W2097029797 hasConceptScore W2097029797C90924648 @default.
• W2097029797 hasIssue "2" @default.
• W2097029797 hasLocation W20970297971 @default.
• W2097029797 hasLocation W20970297972 @default.
• W2097029797 hasOpenAccess W2097029797 @default.
• W2097029797 hasPrimaryLocation W20970297971 @default.
• W2097029797 hasRelatedWork W1481820868 @default.
• W2097029797 hasRelatedWork W1984775533 @default.
• W2097029797 hasRelatedWork W2010230997 @default.
• W2097029797 hasRelatedWork W2070587601 @default.
• W2097029797 hasRelatedWork W2072767112 @default.
• W2097029797 hasRelatedWork W2151031435 @default.
• W2097029797 hasRelatedWork W2320097775 @default.
• W2097029797 hasRelatedWork W2417634857 @default.
• W2097029797 hasRelatedWork W2471989939 @default.
• W2097029797 hasRelatedWork W3013194840 @default.
• W2097029797 hasVolume "76" @default.
• W2097029797 isParatext "false" @default.
• W2097029797 isRetracted "false" @default.

• next